Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Operating Expenses | 4,596 | 5,449 | 6,280 | 3,582 | 4,662 |
| Operating Income | -4,596 | -5,449 | -6,280 | -3,582 | -4,662 |
| Interest Expense | 2 | 2 | 2 | 2 | 2 |
| Other Income | 385 | 445 | 496 | 1,346 | 0 |
| Pre-tax Income | -4,213 | -5,006 | -5,786 | -2,238 | -4,664 |
| Net Income Continuous | -4,213 | -5,006 | -5,786 | -3,236 | -4,205 |
| Net Income Discontinuous | 0 | 0 | 0 | -312 | -111 |
| Net Income | $-4,213 | $-5,006 | $-5,786 | $-3,548 | $-4,316 |
| EPS Basic Total Ops | -0.08 | -0.10 | -0.11 | -0.07 | -0.08 |
| EPS Basic Continuous Ops | -0.08 | -0.10 | -0.11 | -0.06 | -0.08 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted Total Ops | -0.08 | -0.10 | -0.11 | -0.07 | -0.08 |
| EPS Diluted Continuous Ops | -0.08 | -0.10 | -0.11 | -0.06 | -0.08 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EBITDA(a) | $-4,211 | $-5,004 | $-5,784 | $-2,236 | $-4,662 |